The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease

Abstract Background/Aims Current models of Crohn's disease (CD) describe an inappropriate immune response to gut microbiota in genetically susceptible individuals. NOD2 variants are strongly associated with development of CD, and NOD2 is part of the innate immune response to bacteria. This stud...

Full description

Saved in:
Bibliographic Details
Published in:Inflammatory bowel diseases 2018-02, Vol.24 (3), p.583-592
Main Authors: Kennedy, Nicholas A, Lamb, Christopher A, Berry, Susan H, Walker, Alan W, Mansfield, John, Parkes, Miles, Simpkins, Rachel, Tremelling, Mark, Nutland, Sarah, Parkhill, Julian, Probert, Chris, Hold, Georgina L, Lees, Charlie W
Format: Article
Language:English
Subjects:
Adult
Aged
Case-Control Studies
Crohn Disease - genetics
Crohn Disease - microbiology
Feces - microbiology
Female
Gastrointestinal Microbiome
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Mutation
Nod2 Signaling Adaptor Protein - genetics
Original s–Basic Science
RNA, Ribosomal, 16S - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background/Aims Current models of Crohn's disease (CD) describe an inappropriate immune response to gut microbiota in genetically susceptible individuals. NOD2 variants are strongly associated with development of CD, and NOD2 is part of the innate immune response to bacteria. This study aimed to identify differences in fecal microbiota in CD patients and non-IBD controls stratified by NOD2 genotype. Methods Patients with CD and non-IBD controls of known NOD2 genotype were identified from patients in previous UK IBD genetics studies and the Cambridge bioresource (genotyped/phenotyped volunteers). Individuals with known CD-associated NOD2 mutations were matched to those with wild-type genotype. We obtained fecal samples from patients in clinical remission with low fecal calprotectin (
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izx061